adjuvant parp inhibitors in patients with high-risk early-stage her2-negative breast cancer and g...
Published 6 months ago • 5 plays • Length 15:46Download video MP4
Download video MP3
Similar videos
-
2:44
olympia: adjuvant olaparib in gbrcam, her2-negative, high-risk, early breast cancer
-
0:38
standard of care practice in adjuvant hr breast cancer before asco 2023 #oncology #asco2023 #cancer
-
6:16
asco 2021 - highlights on shifting parpi to early breast cancer: the olympia study
-
9:42
use of immune checkpoint inhibitor pembrolizumab in the treatment of high-risk, early-stage tripl...
-
3:35
the benefits of adjuvant cdk4/6 and parp inhibition in breast cancer
-
7:15
asco 2023 expert report in hr positive, her2 negative breast cancer by catherine harper-wynne
-
46:31
adjuvant therapy | 2023 best of breast conference
-
11:07
adjuvant therapy for early stage er-positive, her2-negative invasive breast cancer
-
1:13:00
expanding the benefits of parp inhibitors to more patients with breast cancer and earlier settings
-
20:25
her2 early-stage breast cancer: peri-operative therapy
-
5:00
olympia: adjuvant olaparib delays recurrence of brca-mutant breast cancer | judy garber
-
9:36
biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer guideline update
-
3:24
what to look forward to in breast cancer at asco 2023
-
3:14
parp inhibitor staves off recurrence in early brca-mutant breast cancer - medpage today
-
10:43
role of patient and disease factors in adjuvant systemic therapy decision-making for early-stage,...
-
27:25
opportunities and challenges in early breast cancer: do parp inhibitors have a role?
-
1:27
dr. litton on the impact of parp inhibitors in breast cancer
-
2:21
olaparib: predicting response in breast cancer
-
2:15
parp inhibitors in metastatic breast cancer: where are we now?